Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Diabetic Retinopathy
Interventions: Online Survey; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Ischemic Optic Neuropathy, Branch Retinal Artery Occlusion, Hemianopia, Leber Hereditary Optic Neuropathy, Acute Zonal Occult Outer Retinopathy
Interventions: LSFG-NAVI; Device
Lead sponsor: Randy Kardon; Other
Eligibility: 18 Years to 99 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes
Interventions: Vessel measurements; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Macular Edema, Cystoid, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more

Conditions: Diabetic Retinopathy
Interventions: Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Retinal Diseases, Telangiectasis
Interventions: ranibizumab 2.0mg; Drug
Lead sponsor: Eye Center of Northern Colorado, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
Interventions: SU011248; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Deafness, Kidney Diseases, Kidney Neoplasms, Neoplasms, Retinal Diseases
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Financial Incentive, Retinal Care DR; Behavioral
Lead sponsor: Retinal Care Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Retinal Vein Occlusions
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinal Vein Occlusion
Interventions: fluocinolone acetonide (Retisert Implant); Device
Lead sponsor: Glenn Jaffe; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Interventions: dexamethasone, ranibizumab, sham; Drug · Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Retinopathy, Diabetic
Interventions: Aflibercept Injection, Sham injection; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diabetes, Diabetic Retinopathy
Interventions: Diabetes Education; Behavioral
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 1,875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Loma Linda, California • Santa Barbara, California • Fort Lauderdale, Florida + 29 more

Conditions: Diabetic Retinopathy
Interventions: triamcinolone acetonide; Drug
Lead sponsor: Edward Hines Jr. VA Hospital; Federal
Eligibility: 25 Years to 80 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions: Anterior Chamber (AC) Tap; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: MK-8748, Aflibercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Long Beach, California • Waterford, Connecticut • Orlando, Florida + 17 more

Conditions: Vitreous Detachment, Diabetic Retinopathy
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Beverly Hills, California • New York, New York • McAllen, Texas + 1 more

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more

Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept; Genetic · Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 25 Years to 89 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more

Conditions: Age-Related Macular Degeneration
Interventions: NG101 AAV gene therapy; Genetic
Lead sponsor: Elisigen, Inc.; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

New Non-invasive Modalities for Assessing Retinal Structure and Function

Retinal Vessel Measurements as Clinically Useful Predictors in Veterans

Vascular Endothelial Growth Factor (VEGF) in Uveitis

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors

PROTECT2: Diabetes Care - Eye Exam

OCT in Retinal Vein Occlusions

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

PST/Laser v. Laser Alone for CSME

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration